福瑞达再次“瘦身”，拟8840万元转让银座商管

Core Viewpoint - The company, Furuida, is divesting its wholly-owned subsidiary, Shandong Lushang Yinzao Commercial Management Co., Ltd. (Yinzao Management), for 88.4028 million yuan to a related party, aiming to optimize resource allocation and focus on its core pharmaceutical and cosmetics businesses [1][5]. Group 1: Transaction Details - Furuida's board approved the transfer of 100% equity of Yinzao Management, which will no longer be included in the consolidated financial statements post-transaction [1]. - The transaction is classified as a related party transaction due to both parties being controlled by the same parent company, Shandong Provincial Commercial Group [1]. Group 2: Financial Performance of Yinzao Management - Yinzao Management's revenue primarily comes from managing internal real estate projects, but it has faced challenges due to state policies affecting state-owned capital's exit from the real estate sector [3]. - The company reported a net loss of 62.35 thousand yuan in 2024, which further increased to 87.68 thousand yuan in the first half of 2025 [3]. Group 3: Strategic Implications for Furuida - By divesting a loss-making non-core business, Furuida aims to reshape its competitive advantage and concentrate on its main sectors [5]. - The company has been actively restructuring, having previously divested eight real estate companies and related debts for a total of 5.901 billion yuan, resulting in a significant shift in revenue structure from real estate to zero [5]. - Despite focusing on pharmaceuticals and cosmetics, Furuida's performance has been under pressure, with a 7.05% decline in revenue to 1.79 billion yuan and a 15.16% drop in net profit to 108 million yuan in the first half of 2025 [5][6]. Group 4: Challenges in Core Business Segments - The decline in performance is attributed to the underperformance of the popular brand, Aier Doctor, which saw a 29.97% decrease in revenue to 451 million yuan in the first half of 2025 [6]. - The pharmaceutical segment also faced challenges, with a 13.87% revenue decline to 207 million yuan, impacted by the expansion of centralized procurement and price reductions of winning products [6].